

CLINICAL UPDATE

Intravenous glutathione for skin lightening: Inadequate safety data

L M Davids,¹ PhD; J C van Wyk,² PhD; N P Khumalo,² MB ChB, FCDerm, PhD

¹ Department of Human Biology, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

² Division of Dermatology, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa

Corresponding author: N P Khumalo (n.khumalo@uct.ac.za)

Background. Glutathione (GSH) is the most abundant naturally occurring non-protein thiol that protects mammalian cells from oxidative stress. Intravenous (IV) GSH for skin lightening is advertised by clinics in South Africa and internationally online, yet to date no published review on the subject exists.

Methods. We conducted a MEDLINE search (to 30 September 2015) of GSH use for skin lightening and of all indications in medicine, to evaluate its safety.

Results. Two controlled clinical trials (GSH capsules: 60 patients; 2% glutathione disulphide lotion: 30 patients) and a case series (GSH lozenges: 30 patients) reported a significantly decreased melanin index. A case series (GSH soap: 15 patients) reported skin lightening based on photography. Two systematic reviews of IV GSH for preventing chemo-induced toxicity and a third review of adjuvant therapy for Parkinson's disease altogether included 10 trials. Most trials reported either no or minimal GSH adverse effects, but all had treatment durations of a few doses (IV) or 4 - 12 weeks. No study reported long-term IV GSH use.

Conclusion. In spite of widespread reported use, there are no studies of IV GSH use for skin lightening or of its safety for chronic use (for any indication). The switch from brown to red melanin production may increase the risk of sun-induced skin cancers in previously protected individuals. Regulatory assessment of systemic GSH administration for cosmetic use by the Medicines Control Council seems urgently warranted to protect consumers from potential side-effects and from complications of IV infusions. This is especially concerning because of reports of GSH bought online. Effective topical GSH may be useful for hyperpigmented skin disorders, but this requires scientific scrutiny. The debate on the merits of cosmetic skin lightening is best handled by multidisciplinary teams.

S Afr Med J 2016;106(8):782-786. DOI:10.7196/SAMJ.2016.v106i8.10878

Dermatologists use depigmenting creams with various active ingredients in the treatment of melasma and post-inflammatory hyperpigmentation.^[1] Skin lightening or bleaching refers to the cosmetic practice of applying depigmenting agents not as treatment for hyperpigmentation but with the deliberate aim of achieving a lighter skin colour. It is a practice that is common in many places (e.g. India, Africa and America) with pigmented populations and a history of improved social status with lighter complexion. Adverse effects are associated with active ingredients (mercury, hydroquinone and potent steroids) in depigmenting creams and are illegal in cosmetics in many countries. Further illegal ingredients in Africa have been shown to be imported from Europe (in spite of a European Union ban).^[2]

Glutathione (GSH) was first discovered by Hopkins^[3] in 1921 in yeasts, and subsequently in other tissues.^[4] It is a tripeptide composed of L-cysteine, glycine and glutamate that is synthesised intracellularly.^[5,6] It is considered the main redox buffer in human cells owing to its large amount of reducing equivalents,^[7] and is an important enzyme cofactor that serves as a neuromodulator in the central nervous system. The tripeptide exists intracellularly either in an oxidised glutathione disulphide (GSSG) or reduced state (GSH), and maintaining an optimal GSH:GSSG ratio in the cell is critical for prevention of oxidative damage and for cell survival (Fig. 1).^[8] An imbalance in GSH and its use as a marker of oxidative stress is reported in many diseases including cancer, neurodegenerative disorders, cystic fibrosis, HIV,^[9] diabetes mellitus,^[10] anorexia nervosa^[11] and autism^[12,13] and in low-birth-weight neonates.^[14]

Reports of systemic skin lightening with GSH have appeared with increasing frequency on social media, and clinics advertise it online

in many countries (Africa, the USA, Canada, Mexico, etc.). Our objective was to conduct a literature search to identify all academic reports of GSH use for skin lightening and all clinical trials of GSH use for all indications in medicine.

Methods

Two MEDLINE searches for studies published up to September 2015 were conducted. The search terms for the first were 'glutathione AND skin lightening', and for the second 'glutathione AND randomised controlled trial'. Inclusion criteria were any treatment report of GSH for skin lightening (or hyperpigmentation) and GSH for any randomised control trial (RCT) for the first and second searches, respectively. Abstracts were read independently by two authors to identify relevant articles.

Results

Nine articles were identified from the first MEDLINE search. Six publications mentioned GSH as part of reviews related to melanin (kojic acid in rats,^[15] piceatannol inhibition of mushroom tyrosinase,^[16] oral zinc sulphate murine hair hypopigmentation,^[17] hydroquinone occupational exposure^[18] (and toxicity for skin lightening)^[19] and natural ingredient-containing treatments for hyperpigmentation.^[20] A seventh article was an extensive review of biochemical mechanisms of how GSH causes depigmentation in cell cultures and laboratory animals.^[21] Five clinical reports (4 published since 2012) of the use of GSH for skin lightening were identified (2 from the MEDLINE search and 3 from references). The first, a pharmacokinetic study of GSH in seven participants, did not measure skin lightening




Fig. 1. GSH and its effect on skin lightening. Reactive oxygen species (ROS) have a direct activation effect on tyrosinase. Reduced GSH neutralises ROS formation and thus indirectly inhibits tyrosinase. At the dopachrome step* of the melanogenic pathway, interaction of thiols such as reduced GSH and cysteine bind with dopaquinone to produce thioldopas and favour phaeomelanogenesis. GST catalyses binding of GSH and dopaquinone. (DOPA = dihydroxyphenylalanine; DHI = dihydroxyindole; DHICA = dihydroxyindole carboxylic acid.)

or report side-effects.^[22] A case series of 15 patients from India treated with a GSH-containing soap for melanosis of the face reported lightening (in 11/15 after 3 months) based on clinical photographs. However, no mention was made of how the conditions for photography were standardised or of follow-up on stopping treatment.^[23] A controlled trial from Thailand tested 250 mg GSH capsules twice daily in two groups each of 30 medical students over 4 weeks. They reported a decreased melanin index measured at six body sites (but statistically significant only at two sites, namely the right side of the face ($p=0.021$) and the sun-exposed left forearm ($p=0.036$)).^[24] Watanabe *et al.*^[25] from Japan reported a significant reduction in the melanin index (mean (standard deviation), week 0: 272.77 (26.17); week 10: 243.47 (26.31)) in subjects treated with a GSSG-containing lotion measured with a Mexameter MX18 (Courage + Khazaka Electronic GmbH, Germany). Investigators and participants also subjectively scored GSSG-treated skin as lighter. The most recent study is an uncontrolled trial of 30 Filipino women. The authors reported a significant reduction in melanin index (measured with a portable mexameter) ($p<0.0001$) after 500 mg GSH lozenges were administered

daily for 8 weeks.^[26] None of the studies reported significant adverse effects or follow-up beyond the study period (Table 1).

Of the plethora of articles retrieved from the second MEDLINE search, we identified 28 systematic reviews of animal studies,^[39–41] GSH-related genetic polymorphisms linked to various cancers (colorectal cancer,^[42] leukaemia,^[43,44] lung cancer,^[45,46] bladder cancer,^[47] gastric cancer,^[48,49] prostate cancer,^[50–53] adult brain tumours,^[54] basal cell carcinoma^[55]) and linked to other disorders (autism,^[12,13] hypertension,^[56,57] respiratory diseases,^[58,59] cataract,^[60] myelodysplastic syndrome,^[61,62] glioma^[63] and male idiopathic infertility.^[64] There were 9 RCTs identified from two systematic reviews of the use of GSH to reduce chemotherapy-induced toxicity (6 cisplatin, 2 axaliplatin, 1 platinum); most suggested less toxicity in GSH groups. A systematic review of GSH as an adjuvant therapy in Parkinson's disease identified one controlled trial^[65] showing doubtful benefit. It was noteworthy that most studies did not report adverse events of GSH, and any reported were mild (Table 1).

Discussion

The idea of GSH-induced hypopigmentation may stem from early studies linking

sulphydryl-containing compounds to the inhibition of melanogenesis or from early anecdotal observations in Parkinson's disease. Proposed mechanisms of its action include inactivation of the melanogenic enzyme, tyrosinase, influencing the switch from eumelanin to phaeomelanin.^[66,67] During melanogenesis, tyrosinase is responsible for the conversion of L-tyrosine to L-DOPA and subsequently to dopaquinone, then the pathway bifurcates to produce eumelanin or phaeomelanin. At a critical point in the melanogenic pathway (asterisk, Fig. 1), thiols (cysteine and GSH) can react with L-dopaquinone to produce glutathionyldopa, or act as a reservoir of L-cysteine by conjugating with L-dopaquinone to produce cysteinyldopa. These two thiodopas substrates serve as a precursor to enhance the switch from eumelanogenesis to phaeomelanogenesis, resulting in lighter skin pigmentation.^[68,69] This effect of GSH on skin pigmentation was reported half a century ago, with black human skin shown to exhibit lower levels of GSH than white skin.^[70] In addition, GSH can act to lighten the skin directly through the quenching of free radicals and peroxides that have been shown to induce tyrosinase activity.^[71] However, more evidence is needed to prove this unequivocally.

GSH therefore has the potential to lighten human skin. However, the only reliable safety data on GSH are of sporadic use during chemotherapy cycles, for a few weeks at most. There are no data on adverse effects of chronic high-dose GSH as used for skin lightening.

All chemotoxicity studies used injectable GSH. Reactive oxygen species are easily decomposed in aqueous solution; this may explain the novelty of drug delivery as lozenges, which may be more stable (although two participants complained about the taste). The oral route reduces potential adverse events associated with intravenous (IV) administration but is associated with low bioavailability. Effective topical GSH^[25] may be useful for dermatologists treating hyperpigmentation, but it is worth noting that GSH as a thiol interacts with metalloid complexes that render it ineffective. Patients should be advised to avoid using GSH with over-the-counter skin lightening creams that may contain mercury.^[1]

All identified published trials report mild or no side-effects of GSH use. However, study duration was a maximum of 12 weeks. We identified one case series that reported intolerable adverse effects leading to discontinuation of 5 mg oral GSH daily as adjuvant treatment for hepatocellular carcinoma (HCC). Seven of 8 patients died within

1 year. However, the very severe prognosis associated with HCC was a likely confounder.^[72] The effect of long-term administration of high doses of GSH on cells or organ systems remains unclear. Further-

more, since GSH causes a switch from eumelanin to phaeomelanin, it may increase UV photosensitivity, DNA damage and skin cancers in previously protected populations.^[73] Of major concern are

Table 1. Current list of human clinical trials associated with GSH

Reference	Country of origin	Subjects, n (sex), age		
	Study type	GSH dose and duration		
	Indication	Study duration	Outcomes	Adverse events
Skin whitening				
Hong <i>et al.</i> , ^[22] 2005	Korea	7 (male), 22 - 23 yr	IV GSH oxidised to GSSG (half-life = 10 min)	None reported
	Cases (uncontrolled)	65.5 (SD 4.5) kg, 50 mg GSH/kg body weight IV over 10 min, 10 d	Loading dose = 1.69 g/kg Maintenance dose = 5.70 g/h/kg to reach extracellular concentration required to suppress intracellular ROS	
Arjinpathana and Asawonda, ^[24] 2012	Bangkok, Thailand	60 (18 male, 42 female), 19 - 22 yr	Significant reduction in melanin indices (UV spots) as measured by VISIA (Canfield Scientific Inc., USA) at all six sites in subjects who received GSH v. controls	Flatulence
	RCT (double-blind, placebo)	250 mg capsules GSH twice daily, 4 wk		
Sriharsha <i>et al.</i> , ^[23] 2015	India	15, 15 - 70 yr	Decreased hyperpigmentation in 11/15 patients after 3 mo	None reported
	Pilot study	3 mo		
	GSH soap: melanosis of the face			
Watanabe <i>et al.</i> , ^[25] 2014	Ibaraki, Japan	30 (female), 30 - 50 yr	Weeks 6 and 10:	Mild erythema of the face (n=1)
	RCT (double-blind, placebo)	2% GSSG lotion twice daily,	Melanin index sign lower GSSG v. placebo	
	Skin whitening	10 wk	Keratin index sign lower GSSG v. placebo	
Handog <i>et al.</i> , ^[26] 2015	Manilla, Phillipines	30 (female), 22 - 42 yr	Decreased melanin index after 2 wk	Sore gums (n=1)
	Single-arm trial (not blinded)	500 mg daily, 8 wk	All subjects showed a significant decrease in melanin index from baseline (p<0.0001)	Undesirable flavour/textture of lozenge (n=1)
	GSH-containing lozenges			
	Skin whitening			
Chemotherapy drugs neuroprotection				
Cascinu <i>et al.</i> , ^[27] 1995	Italy	50	Neuropathy	None reported
	RCT (double-blind, placebo)	GSH 1.5 g/m ² in 100 mL saline IV over 15 min	Week 9: 0 GSH v. 16 placebo	
	Prevent cisplatin toxicity in gastric cancer	600 mg GSH IM, days 2 - 5	Week 15: 4/24 GSH v. 16/18 placebo	
Colombo <i>et al.</i> , ^[28] 1995	Italy	33	Higher (100% dose) cisplatin intensity was received by 56% GSH v. 27% control	None reported
	Random, phase II	50 mg/m ² weekly ± 2.5 g/m ²		
	Prevent cisplatin toxicity in relapsed ovarian cancer	GSH, 9 wk		
Parnis <i>et al.</i> , ^[29] 1995	Australia	12	No significant protection	None reported
	RCT (double-blind, placebo)	GSH 1.5 g/m ² over 15 min		
	Prevent cisplatin toxicity in ovarian cancer	CDDP 40 mg/m ² over 2 h for 2, 3 or 4 consecutive days		
		NR		
Bogliu <i>et al.</i> , ^[30] 1992	Italy	33	Less severe neurotoxicity after co-treatment with all methods	Similar in both groups except oliguria greater in placebo group
	Placebo controlled	CDDP total dose 500 - 675 mg/m ² ± GSH 2.5 g/m ² IV over 15 min, 1 wk		
	Prevent cisplatin toxicity in ovarian cancer			
Smyth <i>et al.</i> , ^[31] 1997	United Kingdom	151 (female), 21 - 76 yr	6 courses of cisplatin, 58% GSH v. 39% control	None reported
	RCT (double-blind, placebo)	6 cycles of 100 mg/m ² ± 3 g/m ² + GSH IV over 15 min, 3 wk	Improved creatinine, GSH 74% v. 62% (p=0.006)	
	Prevent cisplatin toxicity in ovarian cancer		GSH improved depression, emesis, neurotoxicity, hair loss, shortness of breath	

Continued ...

Table 1. (continued) Current list of human clinical trials associated with GSH

Reference	Country of origin Study type Indication	Subjects, n (sex), age GSH dose and duration Study duration	Outcomes	Adverse events
Schmidinger <i>et al.</i> , ^[32] 2000	Austria RCT (blinding, pilot) GSH v. intensive hydration in cisplatin chemo regimen for solid tumours	20 80 mg/m ² , 4 wk GSH 5 g IV + 2 000 mL saline control + 4 000 mL saline + forced diuresis NR	Haemoglobin: GSH 10.7 mg v. placebo 9.5 mg ($p=0.039$) White cells: GSH 3.3×10^3 /mL v. placebo 2.2×10^3 /mL ($p=0.004$) Platelets: GSH 167×10^3 /mL v. placebo 95×10^3 /mL ($p=0.02$)	None reported
Cascinu <i>et al.</i> , ^[33] 2002	Italy RCT (double-blind, placebo) Prevent oxaliplatin toxicity in advanced colorectal cancer	52 GSH 1 500 mg/m ² IV over 15 min prior to oxaliplatin 12 treatment cycles	Neuropathy Cycle 4: 7 GSH v. 11 placebo Cycle 8: 9/21 GSH v. 15/19 placebo Cycle 12: 3 GSH arm v. 8 placebo	None reported
Milla <i>et al.</i> , ^[34] 2009	Italy Oxaliplatin neurotoxicity in colorectal cancer treated with FOLFOX4 adjuvant regimen	27 GSH 1 500 mg/m ² IV or saline solution before oxaliplatin infusion 12 treatment cycles	Reduced neurotoxicity GSH v. placebo ($p=0.0037$)	None reported
Leal <i>et al.</i> , ^[35] 2014	USA RCT (double-blind, placebo) Prevent platinum peripheral neuropathy	185 1.5 g/m ² GSH IV or placebo over 15 min 18 wk	No statistically significant differences in peripheral neurotoxicity, degree of paclitaxel acute pain syndrome, time to disease progression or apparent toxicities	None reported
Neurodegenerative disorders				
Sechi <i>et al.</i> , ^[36] 1996	Italy Cases (uncontrolled) Parkinson's disease	9 600 mg GSH IV twice daily, 30 d, 4 mo	42% decline in disability, therapeutic effect lasted 2 - 4 mo	None reported
Hauser <i>et al.</i> , ^[37] 2009	USA RCT, pilot trial (placebo) Safety and preliminary efficacy in Parkinson's disease	21 1 400 mg GSH IV or placebo 3 times a wk, 4 wk 3 mo	Unified Parkinson's Disease Rating Scale (UPDRS) motor scores higher in GSH group v. placebo	No adverse events due to GSH
Mischley <i>et al.</i> , ^[38] 2015	USA Safety and tolerability of intranasal GSH in Parkinson's disease	30 600 mg/d of intranasal GSH v. placebo (saline) in 3 divided daily doses 3 mo	All groups met tolerability criteria	No adverse events due to GSH

NR = not reported; IM = intramuscular.

potentially severe complications (septicaemia, infective endocarditis and transmission of blood-borne infections) of IV administration of GSH by people with no health qualifications. Recent Food and Drug Administration warnings also point to a need for increased public awareness of potential harm.^[74]

Conclusion

This brief review evaluates recent clinical studies on the use of GSH. Despite widespread use of IV GSH, no clinical report was identified. Large RCTs of long-enough duration and follow-up are warranted for the safe treatment of pigmentary disorders. The psychosocial impact of systemic skin lightening is a Pandora's box best addressed by multidisciplinary teams including social scientists, psychologists and psychiatrists.

Source of funding. Funded by the South African Medical Research Council.

- Jutley GS, Rajaratnam R, Halpern J, Salim A, Emmett C. Systematic review of randomized controlled trials on interventions for melasma: An abridged Cochrane review. *J Am Acad Dermatol* 2014;70(2):369-373. DOI:[10.1016/j.jaad.2013.07.044](https://doi.org/10.1016/j.jaad.2013.07.044)
- Maneli MH, Wiesner L, Tinguley C, et al. Combinations of potent topical steroids, mercury and hydroquinone are common in internationally manufactured skin-lightening products: A spectroscopic study. *Clin Exp Dermatol* 2016;41(2):196-201. DOI:[10.1111/ced.12720](https://doi.org/10.1111/ced.12720)
- Hopkins FG. On an autoxidisable constituent of the cell. *Biochem J* 1921;15(2):286.
- Quastel JH, Stewart CP, Tunnicliffe HE. On glutathione. IV. Constitution. *Biochem J* 1923;17(4-5):586-592.
- Aoyama K, Sub SW, Hamby AM, et al. Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. *Nat Neurosci* 2006;9(1):119-126. DOI:[10.1038/nrn1609](https://doi.org/10.1038/nrn1609)
- Aoyama K, Nakaki T. Impaired glutathione synthesis in neurodegeneration. *Int J Mol Sci* 2013;14(10):21021-21044. DOI:[10.3390/ijms141021021](https://doi.org/10.3390/ijms141021021)
- Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. *Free Radic Biol Med* 2001;30(11):1191-1212. DOI:[10.1016/S0891-5849\(01\)00480-4](https://doi.org/10.1016/S0891-5849(01)00480-4)
- Dickinson DA, Forman HJ. Glutathione in defense and signaling. *Ann N Y Acad Sci* 2002;973(1):488-504. DOI:[10.1111/j.1749-6632.2002.tb04690.x](https://doi.org/10.1111/j.1749-6632.2002.tb04690.x)
- Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. *Biomed Pharmacother* 2003;57(3-4):145-155. DOI:[10.1016/S0753-3322\(03\)00043-x](https://doi.org/10.1016/S0753-3322(03)00043-x)
- Treweek A, Winterburn T, Mackenzie I, et al. N-acetylcysteine inhibits platelet-monocyte conjugation in patients with type 2 diabetes with depleted intraplatelet glutathione: a randomised controlled trial. *Diabetologia* 2012;55(11):2920-2928. DOI:[10.1007/s00125-012-2685-z](https://doi.org/10.1007/s00125-012-2685-z)
- Solmi M, Veronese N, Manzato E, et al. Oxidative stress and antioxidant levels in patients with anorexia nervosa: A systematic review and exploratory meta-analysis. *Int J Eat Disord* 2015;48(7):826-841. DOI:[10.1002/eat.22443](https://doi.org/10.1002/eat.22443)

12. Frustaci A, Neri M, Cesario A, et al. Oxidative stress-related biomarkers in autism: Systematic review and meta-analyses. *Free Rad Biol Med* 2012;52(10):2128-2141. DOI:10.1016/j.freeradbiomed.2012.03.011
13. Main P, Angley MT, O'Doherty CE, Thomas P, Fenech M. The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis. *Nutr Metab (Lond)* 2012;9(1):35. DOI:10.1186/1743-7075-9-35
14. Loui A, Raab A, Maier RF, Brättner P, Obladen M. Trace elements and antioxidant enzymes in extremely low birthweight infants. *J Trace Elem Med Biol* 2010;24(2):111-118. DOI:10.1016/j.jtemb.2009.11.004
15. Chusirir Y, Wongpoomchar R, Kakehashi A, et al. Non-genotoxic mode of action and possible threshold for hepatocarcinogenicity of kojic acid in F344 rats. *Food Chem Toxicol* 2011;49(2):471-476. DOI:10.1016/j.fct.2010.11.027
16. Yokozawa T, Kim YJ. Picetannol inhibits melanogenesis by its antioxidative actions. *Biol Pharm Bull* 2007;30(11):2007-2011. DOI:10.1248/bpb.30.2007
17. Plonka PM, Handjiski B, Michalczyk D, Popik M, Paus R. Oral zinc sulphate causes murine hair hypopigmentation and is a potent inhibitor of eumelanogenesis in vivo. *Br J Dermatol* 2006;155(1):39-49. DOI:10.1111/j.1365-2133.2006.07376.x
18. DeCaprio A. The toxicology of hydroquinone – relevance to occupational and environmental exposure. *Crit Rev Toxicol* 1999;29(3):283-330. DOI:10.1080/1048449991349221
19. Westerhof W, Kooyers TJ. Hydroquinone and its analogues in dermatology – a potential health risk. *J Cosmet Dermatol* 2005;4(2):55-59. DOI:10.1111/j.1473-2165.2005.40202.x
20. Alexis AF, Blackcloud P. Natural ingredients for darker skin types: Growing options for hyperpigmentation. *J Drugs Dermatol* 2013;12(9 Suppl):s123-s127.
21. Villarama CD, Maibach HI. Glutathione as a depigmenting agent: An overview. *Int J Cosmet Sci* 2005;27(3):147-153. DOI:10.1111/j.1467-2494.2005.00235.x
22. Hong S-Y, Gil H-W, Yang J-O, et al. Pharmacokinetics of glutathione and its metabolites in normal subjects. *J Korean Med Sci* 2005;20(5):721-726. DOI:10.3346/jkms.2005.20.5.721
23. Srirharsha M, Reddy KN, Darsini TP, Reddy KS. Glutathione as a whitening agent in the treatment of melanoses of the face. *Int J Pharm Drug Res* 2015;5(1):1-6.
24. Arjipathana N, Asawonda P. Glutathione as an oral whitening agent: A randomized, double-blind, placebo-controlled study. *J Dermatol Treat* 2012;23(2):97-102. DOI:10.3109/09546631003801619
25. Watanabe F, Hashizume E, Chan GP, Kamimura A. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: A double-blind and placebo-controlled clinical trial in healthy women. *Clin Cosmet Investig Dermatol* 2014;7:267. DOI:10.2147/ccid.s68424
26. Handog EB, Datuin MSL, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. *Int J Dermatol* 2015;55(2):153-157. DOI:10.1111/ijd.12999
27. Casciu S, Cordella L, del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. *J Clin Oncol* 1995;13(1):26-32.
28. Colombo N, Bini S, Miceli D, et al. Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. *Int J Gynecol Cancer* 1995;5(2):81-86. DOI:10.1046/j.1525-1438.1995.05020081.x
29. Parnis FX, Coleman RE, Harper PG, et al. A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. *Eur J Cancer* 1995;31A(10):1721. DOI:10.1016/0959-8049(95)00310-F
30. Bogliu G, Marzorati L, Cavaletti G, Frattola L. Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione. *Ital J Neurol Sci* 1992;13(8):643-647. DOI:10.1007/BF02334967
31. Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial. *Ann Oncol* 1997;8(6):569-573.
32. Schmidinger M, Budinsky AC, Wenzel C, et al. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. *Wien Klin Wochenschr* 2000;112(14):617-623.
33. Casciu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. *J Clin Oncol* 2002;20(16):3478-3483. DOI:10.1200/JCO.2002.07.061
34. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattell L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: Effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. *Anticancer Drugs* 2009;20(5):396-402. DOI:10.1097/CAD.0b013e32832a2dc1.
35. Leal AD, Qin R, Atherton PJ, et al. Alliance for Clinical Trials in Oncology. North Central Cancer Treatment Group/Alliance trial N08CA – the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study. *Cancer* 2014;120(12):1890-1897. DOI:10.1002/cncr.28654
36. Sechi G, Deledda MG, Buia G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 1996;20(7):1159-1170. DOI:10.1016/S0278-5846(96)00103-0
37. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. *Mov Disord* 2009;24(7):979-83. DOI:10.1002/mds.22401.
38. Mischler JK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. *Mov Disord* 2015;30(12):1696-1701. DOI:10.1002/mds.26351
39. Villafuerte G, Miguel-Puga A, Murillo Rodriguez E, et al. Sleep deprivation and oxidative stress in animal models: A systematic review. *Oxid Med Cell Longev* 2015;2015:1-15. DOI:10.1155/2015/234952
40. Durg S, Dhadte SB, Vandal R, Shivakumar BS, Charan CS. *Withania somnifera* (Ashwagandha) in neurobehavioural disorders induced by brain oxidative stress in rodents: A systematic review and meta-analysis. *J Pharm Pharmacol* 2015;67(7):879-899. DOI:10.1111/jphp.12398
41. Wang L, Hong G, Li D, Chen X, Han W, Lu Z. [The efficacy of traditional Chinese medicin in animal model of lung injury induced by paraquat: A meta-analysis]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2014;26(6):399-404.
42. Song Q-B, Wang Q, Hu W-G. A systematic review of glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk. *Chin J Cancer Res* 2014;26(3):255. DOI:10.3978/j.issn.1000-9604.2014.06.014
43. Ye Z, Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis. *Eur J Cancer* 2005;41(7):980-989. DOI:10.1016/j.ejca.2005.01.014
44. Xiao Q, Deng D, Li H, et al. GSTT1 and GSTM1 polymorphisms predict treatment outcome for acute myeloid leukemia: A systematic review and meta-analysis. *Ann Hematol* 2014;93(8):1381-1390. DOI:10.1007/s00277-014-2050-z
45. Yang H, Yang S, Liu J, Shao F, Wang H, Wang Y. The association of GSTM1 deletion polymorphism with lung cancer risk in Chinese population: Evidence from an updated meta-analysis. *Sci Rep* 2015;5:9392. DOI:10.1038/srep09392
46. Shi X, Zhou S, Wang Z, Zhou Z, Wang Z, CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: A meta-analysis. *Lung Cancer* 2008;59(2):155-163. DOI:10.1016/j.lungcan.2007.08.004
47. Wu K, Wang X, Xie Z, Liu Z, Lu Y. Glutathione S-transferase P1 gene polymorphism and bladder cancer susceptibility: An updated analysis. *Mol Biol Rep* 2013;40(1):687-695. DOI:10.1007/s11033-012-2109-7
48. Wang H, Zhou Y, Zhuang W, et al. Glutathione S-transferase M1 null genotype associated with gastric cancer among Asians. *Dig Dis Sci* 2010;55(7):1824-1830. DOI:10.1007/s10620-009-0971-5
49. Yoon J, Hyun M-H, Yang J-P, Park M-J, Park S. Ethnic differences in the association of the glutathione S-transferase T1 (GSTT1) null genotype and risk of gastric carcinoma: A systematic review and meta-analysis. *Mol Biol Rep* 2014;41(6):3867-3878. DOI:10.1007/s11033-014-3254-y
50. Yu Z, Li Z, Cai B, et al. Association between the GSTP1 Ile105Val polymorphism and prostate cancer risk: A systematic review and meta-analysis. *Tumor Biol* 2013;34(3):1855-1863. DOI:10.1007/s13277-013-0727-x
51. Cai Q, Wu T, Zhang W, et al. Genetic polymorphisms in glutathione S-transferases P1 (GSTP1) Ile105Val and prostate cancer risk: A systematic review and meta-analysis. *Tumor Biol* 2013;34(6):3913-3922. DOI:10.1007/s13277-013-0979-5
52. Cai Q, Wang Z, Zhang W, et al. Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: A systematic review and meta-analysis. *Tumour Biol* 2014;35(1):247-256. DOI:10.1007/s13277-013-1030-6
53. Liu D, Liu Y, Ran L, Shang H, Li D. GSTT1 and GSTM1 polymorphisms and prostate cancer risk in Asians: A systematic review and meta-analysis. *Tumor Biol* 2013;34(5):2539-2544. DOI:10.1007/s13277-013-0778-z
54. Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: A meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2005;14(7):1784-1790. DOI:10.1158/1055-9965.epi-05-0105
55. Peng H, He Q, Zhu J, Peng C. Effect of GSTM1 polymorphism on risks of basal cell carcinoma and squamous cell carcinoma: A meta-analysis. *Tumour Biol* 2012;34(2):675-681. DOI:10.1007/s13277-012-0595-9
56. Ge B, Song Y, Zhang Y, Liu X, Wen Y, Guo X. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) null polymorphisms and the risk of hypertension: A meta-analysis. *PLoS One* 2015;10(3):e0118897. DOI:10.1371/journal.pone.0118897
57. Eslami S, Sahebkar A. Glutathione-S-transferase M1 and T1 null genotypes are associated with hypertension risk: A systematic review and meta-analysis of 12 studies. *Curr Hypertens Rep* 2014;16(6):1-9. DOI:10.1007/s11906-014-0432-1
58. Minelli C, Granell R, Newton R, et al. Glutathione-S-transferase genes and asthma phenotypes: A Human Genome Epidemiology (HuGE) systematic review and meta-analysis including unpublished data. *Int J Epidemiol* 2009;39(2):539-562. DOI:10.1093/ije/dyp337
59. Piacentini S, Polimanti R, Simonelli I, et al. Glutathione S-transferase polymorphisms, asthma susceptibility and confounding variables: A meta-analysis. *Mol Biol Rep* 2013;40(4):3299-3313. DOI:10.1007/s11033-012-2405-2
60. Liao R-F, Ye M-J, Liu C-Y, Ye D-Q. An updated meta-analysis: Risk conferred by glutathione S-transferases (GSTM1 and GSTT1) polymorphisms to age-related cataract. *J Ophthalmol* 2015;2015:1-10. DOI:10.1155/2015/103950
61. Dahabreh II, Giannotti S, Gota V, Voulgarelis M. GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: A systematic review and meta-analysis. *Int J Cancer* 2010;126(7):1716-1723. DOI:10.1002/ijc.24940
62. Fang M, Zeng W, Huang L, et al. Association between glutathione S-transferase T1 null genotype and risk of myelodysplastic syndromes: A comprehensive meta-analysis. *Tumour Biol* 2013;34(5):2747-2752. DOI:10.1007/s13277-013-0828-6
63. Xia P, Liang Y, Liang G, Liu B. Association between GSTP1 Ile105Val polymorphism and glioma risk: A systematic review and meta-analysis. *Tumor Biol* 2014;35(1):493-499. DOI:10.1007/s13277-013-1069-4
64. Li X, Pan J, Liu Q, et al. Glutathione S-transferases gene polymorphisms and risk of male idiopathic infertility: A systematic review and meta-analysis. *Mol Biol Rep* 2013;40(3):2431-2438. DOI:10.1007/s11033-012-2323-3
65. Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. *Cancer Database Syst Rev* 2014, Issue 3. Art. No.: CD005228. DOI:10.1002/14651858.CD005228.pub4
66. Villarama C, Maibach HI. Glutathione as a depigmenting agent: An overview. *Int J Cosmet Sci* 2005;27(3):147-153. DOI:10.1111/j.1467-2494.2005.00235.x
67. Ebanks JP, Wickett RR, Boissy RE. Mechanisms regulating skin pigmentation: The rise and fall of complexion coloration. *Int J Mol Sci* 2009;10(9):4066-4087. DOI:10.3390/ijms10094066
68. Del Marmol V, Beermann F. Tyrosinase and related protein in mammalian pigmentation. *FEBS Lett* 1996;381(3):165-168. DOI:10.1016/0014-5793(96)00109-3
69. Benedetto J-P, Ortonne J-P, Voulot C, Khatchadourian C, Prota G, Thivolet J. Role of thiol compounds in mammalian melanin pigmentation. II. Glutathione and related enzymatic activities. *J Invest Dermatol* 1982;79(6):422-424. DOI:10.1111/1523-1747.ep12530631
70. Halprin KM, Ohkawara A. Glutathione and human pigmentation. *Arch Dermatol* 1966;94(3):355-357. DOI:10.1001/archderm.94.3.355
71. Karg E, Odh G, Wittbjer A, Rosengren E, Rorsman H. Hydrogen peroxide as an inducer of elevated tyrosinase level in melanoma cells. *J Invest Dermatol* 1993;100(Suppl 2):209S-213S. DOI:10.1111/1523-1747.ep12465218
72. Dalhoff K, Ranek L, Mantoni M, Poulsen HE. Glutathione treatment of hepatocellular carcinoma. *Liver* 1992;12(5):341-343. DOI:10.1111/j.1600-0676.1992.tb00583.x
73. Wenczel E, van der Schaaf GP, Roza L, et al. (Pheo) melanin photosensitizes UVA-induced DNA damage in cultured human melanocytes. *J Invest Dermatol* 1998;111(4):678-682. DOI:10.1046/j.1523-1747.1998.00357.x
74. Food and Drug Administration. Injectable Skin Lightening Products: What You Should Know. <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm460788.html> (accessed 5 January 2015).

Accepted 11 April 2016.